Tags

Type your tag names separated by a space and hit enter

Enhanced motility of KGF-transfected breast cancer cells.
Anticancer Res. 2006 Mar-Apr; 26(2A):961-6.AR

Abstract

BACKGROUND

In a previous study, we reported that keratinocyte growth factor (KGF) produced a rapid increase in the motility of ER-positive breast cancer cells. Others have demonstrated that KGF treatment in rodent species produces rapid mammary ductal hyperplasia. Epithelial cells do not produce KGF; thus, in the present study, MCF-7 cells were stably transfected with a KGF-expressing vector and the motility and morphology of the transfected, non-transfected and empty vector cell lines compared.

MATERIALS AND METHODS

A mammalian expression vector containing a KGF cDNA was transfected into MCF-7/beta cells, and two stable clones (MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9) were identified. Western blotting of conditioned medium from these clones was used to confirm the expression of KGF. The motility of wild-type and KGF-transfected MCF-7 cells was compared using time-lapse videomicroscopy and a cell culture wounding model which examined cell migration over a period of 1-3 days.

RESULTS

The Western blots demonstrated that the expression of KGF in both the MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9 cell lines was higher than the wild-type and MCF-7/beta cell lines. The cell proliferation and migration distance was significantly greater for both KGF-transfected MCF-7 cell lines than the wild-type and MCF-7/beta cell lines under the same experimental conditions. Further, changes in motile morphology were observed in both the MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9 cell lines. In addition, the MCF-7/beta/KGF-T8 clone was found to produce much larger tumors than both the MCF-7/beta/KGF-T9 and EV clones in mouse xenografts. These results indicated that autocrine production of KGF in the KGF-transfected MCF-7 cell lines enhanced cell migration, migration-related morphology and xenograft tumor growth.

CONCLUSION

KGF-transfected MCF-7 cells displayed a much greater motility than non-transfected cells, confirming the KGF motility enhancement effect which we previously reported. The use of KGF-transfected breast cancer cells in the xenograft model may help to study the mechanism of KGF-mediated cell motility and to identify specific KGF antagonists that may be used to prevent or impede KGF-mediated metastatic progression.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center and InterGenetics Incorporated, Oklahoma City, OK 73117, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

16619493

Citation

Zang, Xiao-Ping, et al. "Enhanced Motility of KGF-transfected Breast Cancer Cells." Anticancer Research, vol. 26, no. 2A, 2006, pp. 961-6.
Zang XP, Bullen EC, Manjeshwar S, et al. Enhanced motility of KGF-transfected breast cancer cells. Anticancer Res. 2006;26(2A):961-6.
Zang, X. P., Bullen, E. C., Manjeshwar, S., Jupe, E. R., Howard, E. W., & Pento, J. T. (2006). Enhanced motility of KGF-transfected breast cancer cells. Anticancer Research, 26(2A), 961-6.
Zang XP, et al. Enhanced Motility of KGF-transfected Breast Cancer Cells. Anticancer Res. 2006 Mar-Apr;26(2A):961-6. PubMed PMID: 16619493.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhanced motility of KGF-transfected breast cancer cells. AU - Zang,Xiao-Ping, AU - Bullen,Elizabeth C, AU - Manjeshwar,Sharmila, AU - Jupe,Eldon R, AU - Howard,Eric W, AU - Pento,J Thomas, PY - 2006/4/20/pubmed PY - 2006/5/12/medline PY - 2006/4/20/entrez SP - 961 EP - 6 JF - Anticancer research JO - Anticancer Res VL - 26 IS - 2A N2 - BACKGROUND: In a previous study, we reported that keratinocyte growth factor (KGF) produced a rapid increase in the motility of ER-positive breast cancer cells. Others have demonstrated that KGF treatment in rodent species produces rapid mammary ductal hyperplasia. Epithelial cells do not produce KGF; thus, in the present study, MCF-7 cells were stably transfected with a KGF-expressing vector and the motility and morphology of the transfected, non-transfected and empty vector cell lines compared. MATERIALS AND METHODS: A mammalian expression vector containing a KGF cDNA was transfected into MCF-7/beta cells, and two stable clones (MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9) were identified. Western blotting of conditioned medium from these clones was used to confirm the expression of KGF. The motility of wild-type and KGF-transfected MCF-7 cells was compared using time-lapse videomicroscopy and a cell culture wounding model which examined cell migration over a period of 1-3 days. RESULTS: The Western blots demonstrated that the expression of KGF in both the MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9 cell lines was higher than the wild-type and MCF-7/beta cell lines. The cell proliferation and migration distance was significantly greater for both KGF-transfected MCF-7 cell lines than the wild-type and MCF-7/beta cell lines under the same experimental conditions. Further, changes in motile morphology were observed in both the MCF-7/beta/KGF-T8 and MCF-7/beta/KGF-T9 cell lines. In addition, the MCF-7/beta/KGF-T8 clone was found to produce much larger tumors than both the MCF-7/beta/KGF-T9 and EV clones in mouse xenografts. These results indicated that autocrine production of KGF in the KGF-transfected MCF-7 cell lines enhanced cell migration, migration-related morphology and xenograft tumor growth. CONCLUSION: KGF-transfected MCF-7 cells displayed a much greater motility than non-transfected cells, confirming the KGF motility enhancement effect which we previously reported. The use of KGF-transfected breast cancer cells in the xenograft model may help to study the mechanism of KGF-mediated cell motility and to identify specific KGF antagonists that may be used to prevent or impede KGF-mediated metastatic progression. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/16619493/Enhanced_motility_of_KGF_transfected_breast_cancer_cells_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=16619493 DB - PRIME DP - Unbound Medicine ER -